Compare FINW & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | ELTX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.4M | 185.4M |
| IPO Year | 2021 | 2014 |
| Metric | FINW | ELTX |
|---|---|---|
| Price | $13.73 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 43.0K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.51 | ★ 39.29 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $67.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.82 | $2.66 |
| 52 Week High | $22.49 | $16.00 |
| Indicator | FINW | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 35.97 |
| Support Level | $13.28 | $2.72 |
| Resistance Level | $14.70 | $9.62 |
| Average True Range (ATR) | 0.67 | 0.30 |
| MACD | -0.05 | 0.25 |
| Stochastic Oscillator | 48.59 | 28.33 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.